(E)-5-cholesten-3-one oxime | 63085-02-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (E)-5-cholesten-3-one oxime
• 英文别名: (NE)-N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine
• CAS: 63085-02-9
• 化学式: C₂₇H₄₅NO
• 分子量: 399.66
• InChiKey: LSMADYLNMNRREO-SIWSWZRQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-胆甾烯-3-酮 在 吡啶 、 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 0.42h， 生成 (Z)-5-cholesten-3-one oxime 、 (E)-5-cholesten-3-one oxime
  参考文献：
  名称：

  使用Trofimov反应将吡咯与类固醇骨架退火

  摘要：

  DOI：

  10.1023/a:1014803325701

文献信息

• Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof
  申请人：Bordet Thierry

  公开号：US20060217358A1

  公开（公告）日：2006-09-28

  Compound of formula I where X=O or ═N—OH group, R represents a group chosen from A=hydrogen or together with B a carbon-carbon bond, B=hydrogen, hydroxy or together with A a carbon-carbon bond, C, D, E, F=hydrogen or together with D a carbon-carbon bond, or the one of its addition salts with pharmaceutically acceptable acids, with the exception of a few compounds, as a medicament, use in particular as neuroprotectors, novel compounds of formula I and pharmaceutical compositions.

  化合物I的化学式如下，其中X可以是O或═N—OH基团，R代表从以下组中选择的一种：A=氢或与B一起形成碳-碳键，B=氢、羟基或与A一起形成碳-碳键，C、D、E、F=氢或与D一起形成碳-碳键，或其与药学上可接受的酸的一种或多种加成盐，除了少数化合物外，作为药物，特别是作为神经保护剂，化合物I的新型化合物和制药组合物。
• USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS
  申请人：BORDET Thierry

  公开号：US20100216752A1

  公开（公告）日：2010-08-26

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an ═N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种用于向需要神经保护的患者提供神经保护的方法，包括给予化合物I的神经保护有效量，其中X是氧原子或═N—OH基团，R选自以下组合：A是氢原子，或者与B一起形成碳-碳键，B是氢原子、羟基或者与A一起形成碳-碳键，C是氢原子，或者与D一起形成碳-碳键，D是氢原子，或者与C一起形成碳-碳键，E是氢原子，或者与F一起形成碳-碳键，F是氢原子，或者与E一起形成碳-碳键，或者与药学上可接受的酸形成加成盐。
• METHOD FOR PROVIDING NEUROPROTECTION
  申请人：Bordet Thierry

  公开号：US20120309721A1

  公开（公告）日：2012-12-06

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an =N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种为需要神经保护的患者提供神经保护的方法，包括给予化合物I的神经保护有效剂量，其中X是氧原子或=N-OH基团，R从以下组中选择：A是氢原子或与B一起形成碳-碳键，B是氢原子、羟基或与A一起形成碳-碳键，C是氢原子或与D一起形成碳-碳键，D是氢原子或与C一起形成碳-碳键，E是氢原子或与F一起形成碳-碳键，F是氢原子或与E一起形成碳-碳键，或与药学上可接受的酸形成加成盐。
• METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY
  申请人：BORDET Thierry

  公开号：US20120316141A1

  公开（公告）日：2012-12-13

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an ═N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种为需要神经保护的患者提供神经保护的方法，包括给予化学式I中X为氧原子或═N—OH基团，R选自以下组合的神经保护有效量的化合物：A为氢原子或与B一起形成碳-碳键，B为氢原子、羟基或与A一起形成碳-碳键，C为氢原子或与D一起形成碳-碳键，D为氢原子或与C一起形成碳-碳键，E为氢原子或与F一起形成碳-碳键，F为氢原子或与E一起形成碳-碳键，或与药用可接受酸形成加合物的盐。
• MODIFIED iRNA AGENTS
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20130211063A1

  公开（公告）日：2013-08-15

  The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

  本发明涉及iRNA剂，其中最好包括一个单体，其中核糖基团已被替换为除核糖外的基团。包括这样的单体可以允许调节iRNA剂的一个属性，例如，通过使用非核糖基团作为配体或其他实体（例如，亲脂性基团，例如胆固醇）的点，直接或间接地被系。本发明还涉及制备和使用这种修改的iRNA剂的方法。